Jeffrey Pott - AstraZeneca PLC General Counsel
| AZNCF Stock | USD 135.35 4.95 3.53% |
Executive
Mr. Jeffrey A. Pott is General Counsel of AstraZeneca Plc. He was appointed General Counsel in January 2009 and has overall responsibility for all aspects of AstraZenecas Legal and IP function. He joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for IP, antitrust and product liability litigation. Before joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and antitrust advice and litigation. He received his bachelors degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law. since 2009.
| Tenure | 15 years |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| George Gunn | Novartis AG ADR | 63 | |
| Shannon Klinger | Novartis AG ADR | 49 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| James Sabry | Roche Holding Ltd | 59 | |
| Aharon Gal | Novartis AG ADR | N/A | |
| Susan ONeal | Organon Co | N/A | |
| Rachel Stahler | Organon Co | 48 | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Adrian Kemp | AstraZeneca PLC ADR | N/A | |
| Samir Shah | Novartis AG ADR | N/A | |
| Richard Francis | Novartis AG ADR | 50 | |
| Susanne Fiedler | Organon Co | 56 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Sophie KornowskiBonnet | Roche Holding Ltd | 54 | |
| Thomas Larsen | AstraZeneca PLC ADR | N/A | |
| Susan MD | AstraZeneca PLC ADR | 58 | |
| Vittorio Nisita | Organon Co | 55 | |
| Pierre Chancel | Sanofi ADR | 67 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Brian McNamara | Novartis AG ADR | 47 | |
| Montserrat Calvo | Grifols SA ADR | N/A | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | ||
| Sherilyn McCoy, Non-Executive Director | ||
| Genevieve Berger, Non-Executive Director | ||
| Luke Miels, Executive Vice-President GPPS | ||
| Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development | ||
| Paul Hudson, Executive Vice President North America | ||
| Nazneen Rahman, Non-Executive Director | ||
| Jose Baselga, Executive Vice President - Research & Development Oncology | ||
| JeanPhilippe Courtois, Non-Executive Independent Director | ||
| Thomas Larsen, IR Contact Officer | ||
| Katarina Ageborg, Chief Compliance Officer | ||
| Tony Mok, Non-Executive Director | ||
| Mark Mallon, Executive Vice President International | ||
| Fiona Cicconi, Executive Vice-President Human Resources | ||
| Deborah DiSanzo, Non-Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Shriti Vadera, Non-Executive Independent Director | ||
| Leif Johansson, Non-Executive Independent Chairman of the Board | ||
| Leon Wang, Executive Vice President - Asia Pacific | ||
| Ann Cairns, Non-Executive Director | ||
| Adrian Kemp, Company Secretary | ||
| Cornelia Bargmann, Non-Executive Director | ||
| Tim JacksonSmith, Non-Executive Director | ||
| Jefrey Pott, General Counsel and Member of Disclosure Committee | ||
| Graham Chipchase, Non-Executive Independent Director | ||
| David Smith, Executive VP of Operations and Information Services | ||
| Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| Baroness Vadera, Non-Executive Independent Director | ||
| MBA DVM, CEO Director | ||
| Aradhana MD, CFO Director | ||
| Philip Broadley, Director | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President Europe | ||
| David Fredrickson, Executive Vice-President Global Head Oncology Business Unit | ||
| Gonzalo Vina, Head Relations | ||
| Bahija Jallal, Executive Vice President MedImmune | ||
| Rudolph Markham, Non-Executive Independent Director | ||
| Menelas Pangalos, Executive Vice President - Innovative Medicines | ||
| Bruce Burlington, Non-Executive Independent Director | ||
| Marcus Wallenberg, Non-Executive Director | ||
| Iskra Reic, Executive Vice-President Europe |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AstraZeneca PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AstraZeneca PLC's short interest history, or implied volatility extrapolated from AstraZeneca PLC options trading.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving against AstraZeneca Pink Sheet
| 0.75 | TLK | Telkom Indonesia Tbk Financial Report 26th of April 2024 | PairCorr |
| 0.62 | VFS | VinFast Auto Financial Report 20th of May 2024 | PairCorr |
| 0.52 | NVSEF | Novartis AG | PairCorr |
| 0.48 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the AstraZeneca PLC information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for AstraZeneca Pink Sheet analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |